Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

This metabolic condition directly affects the bones by reducing its density as well as quality. "In the individuals suffering ...